Weekly Recap | Tilray Brands -7.57%, closing in on a 52-week low
I'm LongbridgeAI, I can summarize articles.Tilray Brands (TLRY) fell 7.57% this week to $2.81, while the S&P 500 slipped 0.47%, putting the stock about 7.1 percentage points behind the benchmark. The pattern was flat-to-down: Monday and Tuesday held near $3.03, Wednesday broke below $3.00, Thursday bounced briefly to $2.93, and Friday pushed lower again to touch the 52-week low at $2.80 before closing at $2.81.
The Week
Tilray Brands (TLRY) fell 7.57% this week to $2.81, while the S&P 500 slipped 0.47%, putting the stock about 7.1 percentage points behind the benchmark. The pattern was flat-to-down: Monday and Tuesday held near $3.03, Wednesday broke below $3.00, Thursday bounced briefly to $2.93, and Friday pushed lower again to touch the 52-week low at $2.80 before closing at $2.81.
Key Events
Tilray reported first-quarter results early Tuesday, framing them as evidence of a transformed business, though the shares barely moved that day. On Thursday, its Blue Point Brewing unit hosted the 22nd annual Cask Ales Festival, a brand event outside the core cannabis-pharma segment. Several reports tracked analyst price targets: on 22 October the average target was cut 13.22% to $10.02, and on 24 October the consensus target was cut another 12.73% to $7.13. Friday’s 52-week low came in the same window as those downward revisions.
Analyst Ratings
Of the 10 brokers covering the stock, 3 rate it a buy and 7 rate it hold, with no underperform or sell ratings. The consensus recommendation is buy, and the consensus target of $5.61 sits about 99.68% above the $2.81 close. Targets range from $4.00 to $12.00, a wide spread that points to disagreement. Within the pharmaceutical industry, Tilray ranks 45th out of 203 stocks by analyst rating.
The Week Ahead
The macro calendar is crowded: Dallas Fed manufacturing on Monday, then durable goods, FHFA and Case Shiller home prices, new home sales, Richmond Fed and consumer confidence on Tuesday. On the company side, the next report is fiscal Q2 2027, scheduled for 8 January 2027, with an estimated loss of $0.158 per share and revenue of $265m. The question is whether this week’s pressure on lower-priced small-caps carries into the new week as macro data lands.
In Short
The stock closed near its 52-week low, while the consensus target remains almost double the spot price, but the wide target range shows real dispersion among analysts. The latest session’s flow shows large-lot money as a net seller, and the week’s volume ran above the mid-term median as the price floor kept moving lower. The next test is whether the macro releases soften or reinforce that pressure, and what guidance arrives with next quarter’s earnings.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.